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Abstract: Myotonic dystrophy type 1 (DM1) is caused by CTG-repeat expansions leading to a
complex pathology with a multisystemic phenotype that primarily affects the muscles and brain.
Despite a multitude of information, especially on the alternative splicing of several genes involved
in the pathology, information about additional factors contributing to the disease development is
still lacking. We performed RNAseq and gene expression analyses on proliferating primary human
myoblasts and differentiated myotubes. GO-term analysis indicates that in myoblasts and myotubes,
different molecular pathologies are involved in the development of the muscular phenotype. Gene
set enrichment for splicing reveals the likelihood of whole, differentiation stage specific, splicing
complexes that are misregulated in DM1. These data add complexity to the alternative splicing
phenotype and we predict that it will be of high importance for therapeutic interventions to target
not only mature muscle, but also satellite cells.
Keywords: myotonic dystrophy type 1; human primary muscle cell culture; transcriptomics; splicing
1. Introduction
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder with wide ranging
effects starting from skeletal muscle weakness, wasting and myotonia, cardiac arrhythmia,
cataracts and insulin resistance, up to central nervous system dysfunctionality, sleep-wake
cycle disturbances, endocrine dysfunction, frontal balding and a shortened lifespan [1–4].
Estimations of the prevalence of DM1 are about 1 in 8000 or fewer [5,6]. The predom-
inant muscle involvement makes DM1 one of the most frequent muscular dystrophies
in adulthood.
The occurrence, combination and severity of symptoms is highly variable and posi-
tively correlated to a pathological CTG-repeat expansion in the 3′ UTR of the DMPK (DM1
protein kinase) gene [7,8]. Up to 35 CTG triplets in blood derived DNA are considered
normal, a repeat length between 35 and 49 is considered to be a premutation. Between
50 and ~150 repeats a mild expression of the phenotype has been observed and ~100 to
~1000 CTG repeats were identified in patients with classical DM. Repeats consisting of
more than 1000 CTG-triplets usually result in congenital DM, the most severe expression
of the disease [9]. The extended CTG-repeats are unstable and tend to expand further.
This results in anticipation, an increase in the CTG-repeat length in offspring paralleled by
earlier onset and severer disease symptoms compared to their parents [10–12]. The sexual
inheritance also affects the severity of the disease: maternal inheritance results in more
severe clinical features than paternal inheritance [13,14]. Furthermore, somatic mosaicism
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has been observed in DM1: a tissue-specific and age-dependent length heterogeneity of the
DMPK CTG-repeat [15,16].
The main pathomechanism described for DM1 is RNA-toxicity caused by the for-
mation of hairpin structures in the DMPK RNA transcript due to expanded CUG re-
peats [17,18]. The RNA gain-of-function paradigm is supported by the expression of CUG
expansions independent of the DMPK locus in transgenic mice, which cause a severe DM1-
like phenotype [19]. Regarding the mechanism by which these repeat expansions result in
the DM1 phenotype, there are several proposed theories [20]. These include (i) alternative
splicing of several mRNAs [21–24], (ii) altered transcriptional regulation [25–27], (iii) inhib-
ited translation [28,29], (iv) repeat associated non-ATG (RAN) translation resulting in the
presence of toxic peptides [30–32], (v) alternative polyadenylation of several mRNAs [33]
and (vi) miRNA misregulation [27,34–39]. These mechanisms are not exclusive; however,
they do contribute to the complex clinical phenotype.
The mechanism leading to a disbalanced splicing network originates directly from the
formation of the hairpin structure in the DMPK mRNA, whose CUG expansion-driven sec-
ondary structure is recognized by diverse RNA-binding proteins, for instance muscleblind
family members (MBNL1-3) [40,41]. The subsequent sequestration of MBNL is tantamount
to its depletion from the nucleoplasm and with this, loss of function. At the same time,
another splicing factor, CUGBP elav-like family member 1 (CELF1), is hyperphosphory-
lated and thus stabilized, leading to a gain in function [42,43]. Splicing dysregulation of
several key transcripts has been shown to be involved in the development of tissue spe-
cific pathologies in DM1. Examples for genes affected by this missplicing include CLCN1
(chloride voltage-gated channel 1) [44,45], DMD (dystrophin) [46], RYR1 (ryanodine re-
ceptor 1) [47], INSR (insulin receptor), and BIN1 (bridging integrator 1) [48]. Interestingly,
many of the reported alternative splicing events represent a shift from adult to embryonic
splicing patterning [49]. Healthy muscle tissue undergoes an MBNL/CELF-dependent,
postnatal switch of alternative splicing patterns necessary to match the increasing demands
of adult muscle. While MBNL1 levels are low in early embryonic stages and increase
during development, CELF1 expression follows the exact opposite order [49,50]. Although
MBNL and CELF1 imbalance accounts for a whole range of missplicing events in DM1,
and thus have been a main scientific interest for a long time, the phenotypic presentation is
unlikely to be caused entirely by those two factors alone. Indeed, a broad splicing network
misregulation appears likely as the basis of DM1. Consistently, more splicing factors have
been identified to regulate alternative splicing events in DM1, among them STAU1 and
HNRNPA1 [51,52].
Apart from changes to the splicing pattern, which have been subject to numerous
studies, there are also indications that gene expression alterations are playing a role in
DM1. Examples are MBNL1 itself [53], but also various ion channels like calcium, sodium
and potassium channels [53], as well as transcription factors such as MYOG, MYOD and
SP1 [54]. MYOG and MYOD are both downregulated in DM1 and thus probably cause the
aberrant and delayed differentiation process described in DM1 myoblast cell culture [55,56],
possibly explaining poor muscle regeneration potential in patients. Furthermore, several
signalling pathways are known to be affected through downregulated activity of kinases
such as protein kinase B (AKT), MAPK and ERK, further contributing to the differentiation
defect phenotype but also to metabolic dysregulation and autophagy [54]. Compared to
the investigation of alternative splicing very little research has been focused on pathways
affected by differential gene expression. A large study performed on muscle biopsies
from DM1 patients and healthy controls proposed downregulation of cell adhesion and
translation, as well as upregulation of mitochondrial metabolic pathways [57].
It will be of high interest for upcoming therapeutic approaches to know which defects
are playing an important role in the pathomechanism at which stage of differentiation.
Thus, we performed an analysis of gene expression alterations and pathway regulation
in proliferating primary myoblasts as well as differentiated myotubes gained from DM1
patients and compared them to materials gained from non-disease controls.
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2. Results
2.1. Differential Gene Expression in DM1 Myoblasts and Myotubes Compared to Non-Disease Controls
First, DM1 samples were investigated for the typical DM1 phenotype. Cells of all DM1
tissue cultures did show nuclear MBNL1 foci (Figure S1A) and DMPK was slightly upregu-
lated in myoblasts as well as myotubes (Figure S1B). To investigate differential expression
of genes between non-disease control and DM1, we performed RNAseq in proliferating
myoblasts and post-mitotic myotubes. To avoid contamination of the myotubes by non-
differentiated cells we isolated multinucleated myotubes by selective trypsin treatment
followed by sedimentation. In total, more than 28,000 genes were identified. Read counts
were analysed using DESeq2. Normalized counts are listed Supplemental Table S1. We
identified 261 genes in proliferating myoblasts and 195 genes in differentiated myotubes
with a log2 fold change > ±1 (adjusted p-value < 0.1) of which 40 genes are shared between
proliferating and differentiated cells (Figure 1; Tables S2 and S3), indicating differences in
gene expression between non-disease controls and DM1 but also between proliferating
myoblasts and post-mitotic myotubes. Gene expression changes were validated using
RT-qPCR for selected genes (Figure S2). Subsequently, we performed an extensive pathway
enrichment analysis using two approaches: classical gene ontology enrichment as well as
gene set enrichment.
Figure 1. Differential gene expression between non-disease control and DM1 for proliferating myoblasts (left) and post-
mitotic myotubes (right) and visualization of the number of genes with a log2 fold change > ±1 for both conditions (at
the top).
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2.2. Pathway Enrichment Analysis: Gene Ontology “Molecular Function”
First, we were interested in the molecular functions of the differential expressed
genes. DAVID GO molecular function enrichment analysis revealed that myoblasts and
myotubes share enrichment of calcium (p-value 0.003 and 0.01) and actin binding (0.09
and 0.002) as well as glutathione transferase activity (0.00004 and 0.04) (Figure 2). Genes
found in the calcium binding cluster represent sarcomeric proteins like actinin (ACTN4)
or calcium homeostasis factors like ASPH, but mostly genes related to cell adhesion and
the extracellular matrix vital for successful differentiation, development of the neuromus-
cular junction as well as wound healing and regeneration. This includes cadherines and
protocadherines (CDH15, PCDH7/19), as well as glycoproteins such as agrin (AGRN) and
proteoglycans (SPOCK1, HSPG2). Actin binding is more enriched in myotubes than in
myoblasts which can be explained by increasing demands of the cellular morphology and
the development towards sarcomeric structure. Consistently, genes of the spectrin–actin
complex like SPTBN5 and ADD3 but also heavy myosin (MYH9) can be found in myotubes.
Glutathione transferase activity is best known for its function in detoxification and response
to reactive oxygen species. Here, several subunits of the glutathione S-transferase (GST) are
differentially expressed in both myoblasts and myotubes. Further, molecular functions only
enriched in myoblasts include PDZ domain binding, indicating a role in signalling path-
ways, and metal ion binding including genes like Na+/K+ ATPases (ATP1A2, ATP1A4) and
RAS p21 protein activator (RASA4). In contrast, in DM1 myotubes there is an enrichment
of histone binding genes like H4C11-15 as well as oxidoreductase activity highlighting
possible changes in metabolism (Figure 2).
Figure 2. GO enrichment analysis for molecular function of genes differentially expressed between non-disease control and
DM1. Significantly enriched molecular functions are shown for proliferating myoblasts (left, green bars) and post-mitotic
myotubes (right, purple bars) with the number of genes in the respective molecular function displayed next to the bars.
2.3. Pathway Enrichment Analysis: Gene Ontology “Signalling”
As there are reports of altered signalling in myoblasts gained from embryos with
congenital DM1 [54], we were looking directly into signalling alterations. We could identify
several genes involved in signalling pathways that are misregulated in DM1. This mis-
regulation was more pronounced in myoblasts than in myotubes (Figure 3). Amongst the
identified gene ontology pathways related to signalling pathways were kinase B-, MAPK-,
WNT and PI3K signalling—all in myoblasts. Decorin (DCN) is downregulated in DM1
myoblasts (log2FC = −4.3) and is reported to positively regulate muscle differentiation
and regeneration through signalling [58]. The NADPH oxidase (NOX4, log2FC = 2.7)
generates specific reactive oxygen species (ROS) which are important signalling molecules
and were shown to influence Ca2+ release through the ryanodine receptor (RYR1), among
others [59]. In myotubes, identified pathways include apoptotic signalling, DNA damage
response, beta-catenin TCF complex assembly as well as GTPase activity. Angiopoietin 1
(ANGPT1), which is downregulated in DM1 myotubes (log2FC = −2.9), plays a role in
muscle regeneration, as described in murine muscle [60]. PLEKHG5, which is upregulated
in DM1 myotubes (log2FC = 1.2), is an activator of the nuclear factor kappa B (NFKB1)
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signalling pathway, which modulates the switch between muscle proliferation and differ-
entiation, and inhibits late-stage differentiation by silencing myofibrillar gene transcription.
Misregulated genes also include the transcription factors MYOCD and SALL1 (Figure 3).
Figure 3. Heat maps showing differences in expression between non-disease controls and DM1 for genes linked to signalling
pathways in proliferating myoblasts (upper panel) and differentiated myotubes (lower panel). Gene names displayed in
grey: p-value < 0.1, in black: p-value < 0.05.
2.4. Pathway Enrichment Analysis: Gene Ontology “Others”
Apart from the interest in signalling, we analysed the data according to the top hits
in pathway enrichment. This revealed, similar to signalling, similarities and differences
between myoblasts and myotubes (Figure 4). In both, extracellular matrix organization
is amongst the top hits. The above mentioned DCN is a member of the small leucine-
rich proteoglycan (SLRP) family regulating collagen fibril assembly and thus, is a key
modulator of ECM assembly. The ECM is closely connected to signalling pathways,
ultimately activating myogenic factors like MYOD and MYOG, at the same time however,
it is necessary for myoblast fusion. Here, genes like DCN, LAMC2 (log2FC = −2.7) and
LOX (log2FC = 1.7) which build the ECM are downregulated in myoblasts, while genes
inducing ECM breakdown like MMP11 are upregulated (log2FC = 2.4). DM1 myotubes
show decreased levels of lumican (LUM), which belongs to the SLRP family and has
similar functions to DCN. In both myoblasts and myotubes, collagens, cadherines and
protocadherines are upregulated, while elastin (ELN) is strongly upregulated in myotubes
only (log2FC = 3.4).
In myoblasts there are also pathways linked to mitochondria (protein insertion into
mitochondrial membrane involved in apoptotic signal pathways, regulation of mitochon-
drial depolarization, ATP hydrolysis-coupled proton transport and the oxidation–reduction
process), but also pathways linked to wound healing and cytokine-mediated signalling. In
myotubes the top hits include chromatin organization and silencing, cellular response to
UV-B, actin cytoskeleton organization and inflammatory response (Figure 4).
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Figure 4. Heat maps showing differences in expression between DM1 and non-disease controls for the top enriched
pathways based on GO-terms in proliferating myoblasts (upper panel) and differentiated myotubes (lower panel). Gene
names displayed in grey: p-value < 0.1, in black: p-value < 0.05.
2.5. Splicing as the Basis of Pathway Alterations
Missplicing is well described for DM1. We confirmed the presence of alternative
splicing events in our tissue cultures on selected genes, including MBNL1 and TNNT2.
LMO7 and TEAD1, both encoding transcription factors, are misspliced preferentially in
myotubes respectively myoblasts (Figure S3). With the specific aim of investigating splicing
alterations, we performed a test for gene set enrichment (GSEA) using the fgsea R package
(results in Tables S4 and S5). Splicing and especially alternative splicing is a very sensitive
process at the basis of gene expression regulation which has different outcomes depending
on spliceosome assembly, splice site recognition and numerous other factors (reviewed
in [61]). Consistently, it was shown that expression changes of only twofold of certain
splicing factors such as SRSF1 can implicate strong effects on proliferation and apoptosis of
more than twofold in cell culture [62]. We thus expect that small changes of a high number
of splicing factors have broad implications, as spliceosome assembly and composition are
affected. Accordingly, we analysed splicing associated genes with fold changes between 1.1
and 2/−1.1 and −2 to reveal if specific splicing pathways are affected in DM1 (Figure 5).
Our data suggest that genes linked to alternative splicing via spliceosome, spliceosomal
complex assembly, and mRNA 5′ splice site recognition are misregulated in both DM1
myoblasts and myotubes as well as adult muscle. Further, genes associated with positive
regulation of mRNA splicing via spliceosome are downregulated in myoblasts, while in
myotubes, pathways linked to mRNA splice site selection, mRNA 3′ splice site recognition,
and negative regulation of RNA splicing are enriched. In muscle biopsies, we found all of
these pathways affected. However, most striking was the clear cut-off between up- and
downregulation. Pathways generally linked to constitutive splicing (complex assembly)
are downregulated, while alternative splicing is upregulated. Notably, core components of
the spliceosome machinery are underrepresented in our data and the muscle biopsy data;
most splicing related genes belong to the category of accessory components important for
recognition of specific splice sites rather than the splicing reaction itself. This might be a
reason for the strong effects of DM1 on specific tissue types and transcripts rather than
splicing in general. Members of the RNA-binding motif (RBM) family are upregulated in
myoblasts, myotubes and adult muscle and play roles in alternative splicing via splice site
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selection. Interestingly, several studies have shown that, for example, RBM5 regulates the
cell cycle and apoptosis while RBM24 is important for striated muscle differentiation, thus
integrating well in our analysis so far [63,64]. Survival motor neurons 1 and 2 (SMN1/2) are
downregulated in both proliferating and differentiated muscle cells twofold. Deficiency of
SMN1/2 is usually associated with spinal muscular atrophy; however, it was shown that
low levels influence muscle differentiation and maturation through the AKT signalling
pathway [65]. Similar involvements in proliferation, apoptosis and differentiation are
known for many of the genes displayed in Figure 5.
Figure 5. Graphs showing differences in expression between DM1 and non-disease controls for genes linked to splicing in
proliferating myoblasts (upper left), differentiated myotubes (upper right), and muscle biopsies (lower right), sequencing
data published by [57]. The colour of the boxes next to the gene name shows the level of expression change compared to
controls. Genes are grouped depending on their GO-term.
Int. J. Mol. Sci. 2021, 22, 8607 8 of 15
3. Discussion
There is a plethora of data sets regarding missplicing in DM1, yet, it remains elusive
which other pathomechanisms may contribute to this complex disease and how they
might interconnect. We investigated gene expression in a tissue culture differentiation
system using primary human myoblasts collected from DM1 patients and non-disease
controls. This is highly promising in providing insight concerning the development of
novel treatments and helps to answer the question of whether it will be sufficient to target
mature muscle, or if it will be necessary to aim for satellite cells as well.
A general trend we observed, is that there are indeed differences in differentially ex-
pressed genes depending on the cellular differentiation status. While this is not surprising,
looking specifically into affected pathways provides additional information on the disease
etiopathogenesis. A possible contribution to these expression changes could be missplicing
of transcriptions factors. Signalling pathways have been shown to be affected in DM1
before, explicitly in myoblasts gained from embryos with congenital DM1 [54]. Activity
of the kinases protein kinase B (AKT), MAPK and ERK was downregulated in those sam-
ples. Here, we investigated myoblasts gained from adults with myotonic dystrophy and
identified genes involved in the MAPK cascade, protein kinase B (AKT), WNT and PI3K
signalling to be misregulated. While this supports results published on congenital DM, the
lack of a misregulation of these genes in differentiated myotubes indicates the possibility
of a pathomechanism specific for proliferating muscle cells.
Premature senescence has been described for DM1 primary myoblasts [66]. We
previously noticed a repeat-length-dependent increase of nuclear envelope invaginations
in primary human adult onset DM1 myoblasts, which was accompanied by cell cycle
withdrawal of affected cells [67]. We hypothesize that these membrane invaginations are
a result of missplicing events in nuclear envelope proteins like nesprin1 [68] and may
cause further gene expression changes due to alterations of heterochromatin organization.
Conceivably, this contributes to signalling pathways affected in proliferating myoblasts,
resulting in a loss of a certain proportion of proliferating cells due to cell cycle defects. In
both myoblasts and myotubes, we see strong alterations of genes involved in extracellular
matrix (ECM) organization. The ECM is also closely connected to signalling pathways,
ultimately activating myogenic factors like MYOD and MYOG, at the same time however,
it is necessary for myoblast fusion and thus differentiation into mature myotubes.
Differentiation defects in DM1 cells [56] and patient muscle biopsies suggest a lack
of fibre maturation [69]. To investigate this in more detail we decided to isolate differ-
entiated myotubes by minimal trypsin treatment and sedimentation. While there is a
potential loss of material, isolating differentiated myotubes has the benefit of avoiding
contamination of undifferentiated cells. This seems especially important for a disease with
known differentiation defects. The DM1 phenotype correlates approximately with CTG
repeat length: the longer the repeat, the more severe the phenotype. We saw the same
effect in tissue culture: for the sample with the longest repeat (DM1-3), we failed to isolate
enough differentiated myotubes to get sufficient RNAseq reads for analysis. Using the data
available for myotubes, we found an enrichment of genes involved in apoptosis, DNA
damage and repair, histone binding, chromatin organization, and metabolic pathways.
This indicates that the pathological effects in myotubes are different from myoblasts and
increased stress is affecting the fitness of the cells.
Notably, we found the expression of genes linked to pathways involved in responses
to reactive oxygen and inflammation being affected in proliferating and differentiated DM1
cells. This, if also affected in mature muscle fibres, might contribute to the observed fibrosis
in DM1 [70].
The alternative splicing of several genes caused by MBNL/CELF misregulation is
well described to drive the pathology of DM1 [71], and other splicing factors seem to be
involved as well [51,52]. Importantly, our data suggest a considerably higher complexity
of the splicing machinery involved than previously anticipated. Despite being rather
mildly misregulated (log2FC-wise), we can see whole groups of genes linked to alternative
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splicing being upregulated, and the spliceosomal complex assembly downregulated in
myoblasts as well as myotubes. Yet, there are differences between myoblasts and myotubes
regarding genes linked to other splicing related GO-terms. In myotubes, genes involved in
5′ and 3′ splice site recognition are upregulated. A similar picture can be seen for muscle
biopsies [57]. This indicates an altered formation of entire splicing complexes which are
assembled specifically depending on the differentiation stage—and in turn result in a
differentiation stage dependent specific misregulation in DM1. Additional work is required
to further understand the mechanism of this splicing regulation.
In summary, our data suggest that developmental stage-specific missplicing of a
multitude of genes affects different pathways in a stage-dependent manner, and moreover,
that these pathways are highly interconnected (Figure 6). Based on our observations, we
propose that missplicing-induced alterations of gene expression and signalling result in
proliferation, ECM and cytoskeleton misregulation in DM1 myoblasts, ultimately leading
to both cell cycle and differentiation defects, the first of which again influences the second
as fewer myoblasts are present for fusion. In DM1 myotubes, which consequently are
smaller and fewer in number compared to their healthy counterparts, we already observe
inflammatory responses, metabolic defects and DNA damage responses, forecasting the
mature DM1 phenotype. We conclude that it is vital for future therapeutic interventions
to target muscle stem cells, which are the precursor cells for myoblasts and myotubes, in
addition to mature muscle.
Figure 6. Hypothetical effect of the observed misregulated pathways on the cell cycle and differentiation leading to the
DM1 phenotype.
4. Materials and Methods
4.1. Culture of Primary Skeletal Muscle Cells
Primary human myoblasts were cultured in Skeletal Muscle Growth Medium (PELO-
Biotech, Munich, Germany) in an incubator at 37 ◦C and 5% CO2. The growth medium
was supplemented with GlutaMax, 40 U/mL Penicillin, 0.04 mg/mL Streptomycin, and
SkMC Supplement (PELOBiotech, Munich, Germany). Myoblasts were kept from reach-
ing confluency to avoid differentiation. Passage numbers were matched for controls and
patient cells.
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For differentiation, confluent myoblasts were cultivated for 7 days in DMEM contain-
ing 5% horse serum under the same environmental conditions.
4.2. Patients and Non-Disease Controls
Human control and patient materials (Table 1) were obtained with written informed
consent of the respective donors from the Muscle Tissue Culture Collection (MTCC) at the
Friedrich Baur Institute (Department of Neurology, LMU Klinikum, Ludwig Maximilians
University, Munich, Germany). Ethical approval for this study was obtained from the
ethical review committee at the Ludwig Maximilians University, Munich, Germany (IRB-no.
reference 45-14; 4 August 2014).
Table 1. List of patient and control tissue cultures.
Phenotype Age at Biopsy Sex CTG-Repeat Length
DM1-1 DM1 27 M 400–600
DM1-2 DM1 34 M 240–430
DM1-3 DM1 29 F 800–1500
Control-1 — 32 M n.d.
Control-2 — 49 F n.d.
Control-3 — 49 F n.d.
n.d. = not determined; M = male; F = female.
4.3. Myotube Separation
Myotubes were separated from undifferentiated, mononucleated cells by a minimal
trypsin treatment to detach the myotubes. This was followed by gentle centrifugation to
sediment myotubes and separate them from remaining mononucleated cells. All steps
were controlled by light microscopy to observe the success of the separation.
4.4. RNA Isolation
After two washing steps with 1x PBS Trizol® was added to the samples (material
gained from myotube separation respectively plates with myoblasts). The Trizol®/sample
mixture was used directly to isolate the RNA using the Dircet-zolTM RNA MiniPrep Plus
Kit (ZYMO Research, Freiburg, Germany).
4.5. RNA Sequencing
Library preparation was performed using the TruSeq Stranded mRNA Kit (Illumina,
San Diego, CA, USA) with the TruSeq RNA Single Index Set A (Illumina) according to
the recommended procedure. Quality and size distribution of the generated libraries has
been validated using an Agilent 2100 bioanalyzer with high-sensitivity DNA chip (Agilent,
Santa Clara, CA, USA) and DNA yield was measured using the Qubit dsDNA HS Assay Kit
followed by pooling of the libraries in batches of 12 and seqencing of 1.2 pM pooled library
on an Nextseq 500/High Output Flow Cell Cartridge using an paired end, 2 × 76 reads,
single index protocol.
4.6. RT-qPCR
Reverse transcription of RNA was performed using the QuantiTecT Reverse Tran-
scription Kit (Qiagen, Venlo, Netherlands). For the reaction we used the SYBR® Green
Master Mix (Bio-Rad, Hercules, CA, USA) and samples were run and measured on CFX
ConnectTM (Bio-Rad). As reference gene, Ap3d1 was used as it has been shown to be a
suitable reference gene in normal and dystrophic cell culture models of myogenesis [72].
Samples were analysed using the delta Ct method and samples were normalized to the
mean of the controls. Primer sequences are listed in Table S6.
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4.7. Immunofluorescence Staining and Microscopy
Myoblasts were fixed with −20 ◦C cold methanol. Following primary antibodies were
used for staining: MBNL1 (HPA035098, atlas antibodies), Emerin 5D10 (provided by Glenn
E. Morris). Secondary antibodies were Alexa Fluor conjugated and generated in donkey
with minimal species cross-reactivity. For DNA visualization DAPI (4′,6-diamidino-2-
phenylindole) was used.
Images were obtained using an Olympus IX83 inverted microscope equipped with a
100× objective and a digital camera (UC90, Olympus, Shinjuku, Japan).
4.8. Quantification of Splicing Alterations
Splice events covering exon–exon junctions were visualized using Sashimi plots in the
IGV genome browser. Reads spanning exon–exon junctions for the respective splice events
were counted for controls and DM1 samples and visualized as percentage.
4.9. Bioinformatics
Reads were aligned to human genome assembly hg38 using STAR (version 2.6.1b) [73]
and processed using deeptools (version 3.0.2) [74]. All subsequent analysis steps were
conducted in R 4.0.4. BAM files were counted using featureCounts and then analysed with
DESeq2 [75,76]. Normalized reads were used for quality control checks (Figures S4 and S5)
which highlighted the relatively high variance of biological replicates, especially those of
non-disease controls, ultimately leading to a lower number of genes with high significance
and with this, a loss of biologically relevant information. Principal component analysis
(PCA, Figure S4) further shows that there are more differences between undifferentiated
and differentiated than between disease and non-disease samples, which is to be expected.
Moreover, biological replicates more-or-less group together as expected. We decided to
screen for biological meaningful results using standard approaches (DESeq2 + DAVID
GO enrichment analysis) as well as an internal ranking as used in gene set enrichment
analysis (GSEA, Tables S6 and S7). For both, we used the log2 fold changes generated in
DESeq2 transformed with lfcShrink to account for high log2 fold changes [77]. For standard
analysis, we set log2FC > ±1 and p-value < 0.1 to be significantly differentially expressed
between samples, the latter of which can be reasoned by using biological rather than
technical replicates resulting in higher variance, naturally. For splicing analysis however,
we used log2FCs between −1 and 1, but higher than 0.1. Visualization was performed
using packages listed in Supplemental Table S7.
4.10. Muscle Biopsy Data Analysis
Muscle biopsy data for DM1 and controls was previously published by [57]. Raw
sequencing data for four controls and three DM1 samples was downloaded from GEO
(GSE86356) and analysed by following the same workflow for myoblasts and myotubes
described above, including all parameters and cut-offs. Accordingly, data quality was
confirmed through dispersion estimation and PCA (Figures S6 and S7). Additionally,
normalized count reads are listed in Table S8, while DESeq2 and fgsea results can be found
in Tables S9 and S10.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijms22168607/s1.
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